Skip to main content
SpringerLink
Log in

Amivantamab

Lack of efficacy: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Albarran-Artahona V, et al. EP08.02-149 Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab. Journal of Thoracic Oncology 17 (Suppl.): S474 abstr. EP08.02-149, No. 9, Sep 2022. Available from: URL: http://doi.org/10.1016/j.jtho.2022.07.832 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amivantamab. Reactions Weekly 1926, 37 (2022). https://doi.org/10.1007/s40278-022-24315-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-24315-3

Search

Navigation